Confluence Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Juncture Pharmaceuticals is creating novel remedial drugs for neurological improvement problems. The organization's ongoing center is propelling an original medication disclosure that works on friendly and correspondence weaknesses for people with Autism Spectrum Disorders and Fragile X Syndrome.
Confluence Pharmaceuticals has raised $200k across 1 funding round on record, the most recent an undisclosed round of $200k announced in Jun 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Confluence Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2022.
Confluence Pharmaceuticals Funding Rounds
Confluence Pharmaceuticals Founders and Leadership Team
Contact details for the Confluence Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Confluence Pharmaceuticals Funding Compared to Other Biotechnology Startups
Confluence Pharmaceuticals' latest round of $200k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Confluence Pharmaceuticals in Biotechnology and Indianapolis
Companies Similar to Confluence Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Confluence Pharmaceuticals Funding FAQs
What does Confluence Pharmaceuticals do?
Juncture Pharmaceuticals is creating novel remedial drugs for neurological improvement problems. The organization's ongoing center is propelling an original medication disclosure that works on friendly and correspondence weaknesses for people with Autism Spectrum Disorders and Fragile X Syndrome.
How much funding has Confluence Pharmaceuticals raised?
Confluence Pharmaceuticals has raised $200k across 1 round on record. The most recent is an undisclosed round of $200k announced in Jun 2022.
When did Confluence Pharmaceuticals last raise funding?
Confluence Pharmaceuticals' most recent funding round on record is an undisclosed round of $200k, announced in Jun 2022.
Who founded Confluence Pharmaceuticals?
FundedIQ lists Boyd Sturdevant (Founder) at Confluence Pharmaceuticals.
Where is Confluence Pharmaceuticals headquartered?
Confluence Pharmaceuticals is based in Indianapolis, Indiana, United States.
How many employees does Confluence Pharmaceuticals have?
Confluence Pharmaceuticals is in the 1-10 employee band.
How does Confluence Pharmaceuticals' funding compare to other Biotechnology startups?
Confluence Pharmaceuticals' latest round of $200k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Confluence Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Confluence Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.